These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32547647)

  • 21. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
    Jacob A; Shook J; Hutson TE
    Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tivozanib for the treatment of advanced renal cell carcinoma.
    Chatzkel J; Ramnaraign B; Sonpavde G
    Expert Opin Pharmacother; 2022 Jul; 23(10):1135-1142. PubMed ID: 35848061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tivozanib for the treatment of renal cell carcinoma.
    Santoni M; Massari F; Piva F; Carrozza F; Di Nunno V; Cimadamore A; Martignetti A; Montironi R; Battelli N
    Expert Opin Pharmacother; 2018 Jun; 19(9):1021-1025. PubMed ID: 29851529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
    Zengin ZB; Pal SK; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Rini B
    Clin Genitourin Cancer; 2022 Dec; 20(6):553-557. PubMed ID: 36096984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
    Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tivozanib: current status and future directions in the treatment of solid tumors.
    Pal SK; Bergerot PG; Figlin RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1851-9. PubMed ID: 23013465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
    Caquelin L; Gewily M; Mottais W; Tebaldi C; Laviolle B; Naudet F; Locher C
    BMC Cancer; 2022 Apr; 22(1):381. PubMed ID: 35397511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
    Bukowski RM
    Front Oncol; 2012; 2():13. PubMed ID: 22655261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
    Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; Powers D; McDermott DF; Rini BI
    Eur Urol; 2020 Dec; 78(6):783-785. PubMed ID: 32938569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.
    Heseltine J; Allison J; Wong S; Prasad K; Oong ZC; Wong H; Law A; Charnley N; Parikh O; Waddell T; Chow S
    Target Oncol; 2023 Jul; 18(4):593-599. PubMed ID: 37285073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
    Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
    J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
    Szarek M; Needle MN; Rini BI; Pal SK; McDermott DF; Atkins MB; Hutson TE; Escudier BJ
    Clin Genitourin Cancer; 2021 Oct; 19(5):468.e1-468.e5. PubMed ID: 33980467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
    Haberkorn BC; Eskens FA
    Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?
    Grünwald V; Merseburger AS
    Eur J Cancer; 2013 Jul; 49(11):2504-11. PubMed ID: 23601669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
    Wright KM
    Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
    De Luca A; Normanno N
    IDrugs; 2010 Sep; 13(9):636-45. PubMed ID: 20799147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety.
    Xie R; Wu J; Shang B; Bi X; Jiang W; Cao C; Zhou A; Shi H; Shou J
    Cancer Med; 2023 Mar; 12(6):7051-7064. PubMed ID: 36457303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.